Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of AD-209
Condition or disease : hypertension
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Experimental | AD-209+AD-2091 Placebo |
|
| Control group | Active Comparator | AD-2091+AD-209 Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-209 | Drug | PO, Once daily(QD), 8weeks |
| |
| AD-2091 |
| Measure | Description | Time Frame |
|---|---|---|
| Change rate of MSSBP | Change from baseline in mean sitting systolic blood pressure | Baseline, Week 8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kyung Tae Kim, D.V.M | Contact | 82-031-891-5661 | ktkim@addpharma.co.kr | |
| Chang Gyu Park, M.D., Ph.D | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Chang Gyu Park, M.D., Ph.D | Korea University Guro Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Korea University Guro Hospital | Recruiting | Seoul | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41717679 | Derived | Ahn JC, Lee CW, Ahn JH, Lim KH, Sohn IS, Sung KC, Kim KH, Bae JH, Hong SP, Jang WY, Jo SH, Han SH, Kim JB, Lee CJ, Lee JH, Kim N, Cho EJ, Sung JH, Ahn HS, Kim SY, Shin J, Seo SM, Hong SJ, Kim W, Park CG. Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. Hypertension. 2026 Apr;83(4):e25810. doi: 10.1161/HYPERTENSIONAHA.125.25810. Epub 2026 Feb 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
PO, Once daily(QD), 8weeks |
|
| AD-209 Placebo | Drug | PO, Once daily(QD), 8weeks |
|
| AD-2091 Placebo | Drug | PO, Once daily(QD), 8weeks |
|